RSV is the leading cause of infant hospitalizations in the US.
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants - PubMed
Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need f...
pubmed.ncbi.nlm.nih.gov
May 7, 2025 at 9:21 PM
RSV is the leading cause of infant hospitalizations in the US.
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
In a cohort of over 146,000 veterans RSV vaccine effectiveness was estimated at 78·7% (72·2–84·8) against RSV-associated emergency department or urgent care encounters, and 80·3% (65·8–90·1) against RSV-associated hospitalisation.
The #vaccines work.🧪#IDSky
www.thelancet.com/journals/lan...
The #vaccines work.🧪#IDSky
www.thelancet.com/journals/lan...
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
RSV vaccination was effective in preventing RSV-related illness, including associated
health-care use, in adults aged 60 years and older during the 2023–24 respiratory
illness season, supporting curre...
www.thelancet.com
January 23, 2025 at 11:01 PM
In a cohort of over 146,000 veterans RSV vaccine effectiveness was estimated at 78·7% (72·2–84·8) against RSV-associated emergency department or urgent care encounters, and 80·3% (65·8–90·1) against RSV-associated hospitalisation.
The #vaccines work.🧪#IDSky
www.thelancet.com/journals/lan...
The #vaccines work.🧪#IDSky
www.thelancet.com/journals/lan...
A new Cochrane review pooled >100,000 participants across 14 trials of RSV vaccines:
- In older adults,RSV vaccines ⬇️ RSV-related lower resp illness by ~70%.
- In pregnant people, vaccination halved the risk of infants needing medical care for RSV & ⬇️severe dz by ~74%.
www.gavi.org/vaccineswork...
- In older adults,RSV vaccines ⬇️ RSV-related lower resp illness by ~70%.
- In pregnant people, vaccination halved the risk of infants needing medical care for RSV & ⬇️severe dz by ~74%.
www.gavi.org/vaccineswork...
RSV vaccines offer vital protection for the most vulnerable, study confirms
A review of 14 clinical trials involving more than 100,000 participants supports widespread RSV vaccination to reduce severe illness and hospitalisations.
www.gavi.org
October 1, 2025 at 4:05 PM
A new Cochrane review pooled >100,000 participants across 14 trials of RSV vaccines:
- In older adults,RSV vaccines ⬇️ RSV-related lower resp illness by ~70%.
- In pregnant people, vaccination halved the risk of infants needing medical care for RSV & ⬇️severe dz by ~74%.
www.gavi.org/vaccineswork...
- In older adults,RSV vaccines ⬇️ RSV-related lower resp illness by ~70%.
- In pregnant people, vaccination halved the risk of infants needing medical care for RSV & ⬇️severe dz by ~74%.
www.gavi.org/vaccineswork...
A preprint from Quebec following their universal coverage program for Beyfortus (RSV antibody) for infants found that it was *nearly 90% effective* in preventing RSV-related ER visits, hospitalizations and ICU admissions.
August 5, 2025 at 12:18 AM
A preprint from Quebec following their universal coverage program for Beyfortus (RSV antibody) for infants found that it was *nearly 90% effective* in preventing RSV-related ER visits, hospitalizations and ICU admissions.
USA: Respiratory virus activity in the US is high, driven by influenza and RSV. COVID remains relatively low but is rising.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
US respiratory virus activity reaches high levels as flu, RSV spread
www.cidrap.umn.edu
January 10, 2026 at 4:21 AM
USA: Respiratory virus activity in the US is high, driven by influenza and RSV. COVID remains relatively low but is rising.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
#VaccinesWork
"...during the 2023 to 2024 RSV season, RSVpreF substantially reduced severe medically attended RSV disease in an older adult population..."
Estimated Vaccine Effectiveness and Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease jamanetwork.com/journals/jam...
"...during the 2023 to 2024 RSV season, RSVpreF substantially reduced severe medically attended RSV disease in an older adult population..."
Estimated Vaccine Effectiveness and Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease jamanetwork.com/journals/jam...
Estimated Vaccine Effectiveness and Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease
This case-control study estimates vaccine effectiveness of RSVpreF for RSV-related lower respiratory tract disease hospitalizations and emergency department visits in older adults.
jamanetwork.com
December 14, 2024 at 6:12 PM
#VaccinesWork
"...during the 2023 to 2024 RSV season, RSVpreF substantially reduced severe medically attended RSV disease in an older adult population..."
Estimated Vaccine Effectiveness and Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease jamanetwork.com/journals/jam...
"...during the 2023 to 2024 RSV season, RSVpreF substantially reduced severe medically attended RSV disease in an older adult population..."
Estimated Vaccine Effectiveness and Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease jamanetwork.com/journals/jam...
“Paediatricians have described Nirsevimab as a ‘gamechanger’, reducing the number of illnesses and the severity of cases and reducing the spread of RSV to people who are vulnerable.”
There's been a 65 % reduction in RSV in Ireland - #PedSky + #IDSky + #MedSky.
www.irishtimes.com/health/2025/...
There's been a 65 % reduction in RSV in Ireland - #PedSky + #IDSky + #MedSky.
www.irishtimes.com/health/2025/...
‘Significant decline’ in RSV-related illness in babies after high uptake of vaccine
Department of Health introduced new vaccination programme for babies last year
www.irishtimes.com
August 21, 2025 at 6:34 PM
“Paediatricians have described Nirsevimab as a ‘gamechanger’, reducing the number of illnesses and the severity of cases and reducing the spread of RSV to people who are vulnerable.”
There's been a 65 % reduction in RSV in Ireland - #PedSky + #IDSky + #MedSky.
www.irishtimes.com/health/2025/...
There's been a 65 % reduction in RSV in Ireland - #PedSky + #IDSky + #MedSky.
www.irishtimes.com/health/2025/...
First story from our new writer, Laine Bergeson!
RSV vaccine highly effective against hospital admission in older adults, study suggests
82% effective against any RSV-related illness & 87% effective against severe RSV
www.cidrap.umn.edu/r...
Pic: Whispyhistory/Wikimedia Cmmns
RSV vaccine highly effective against hospital admission in older adults, study suggests
82% effective against any RSV-related illness & 87% effective against severe RSV
www.cidrap.umn.edu/r...
Pic: Whispyhistory/Wikimedia Cmmns
November 12, 2025 at 6:23 PM
First story from our new writer, Laine Bergeson!
RSV vaccine highly effective against hospital admission in older adults, study suggests
82% effective against any RSV-related illness & 87% effective against severe RSV
www.cidrap.umn.edu/r...
Pic: Whispyhistory/Wikimedia Cmmns
RSV vaccine highly effective against hospital admission in older adults, study suggests
82% effective against any RSV-related illness & 87% effective against severe RSV
www.cidrap.umn.edu/r...
Pic: Whispyhistory/Wikimedia Cmmns
Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 14, 2026 at 1:23 PM
Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
American Indian and Alaska Native infants experience the highest rates of RSV-related hospitalization in the U.S., but a breakthrough immunization is helping to close the gap
How RSV Immunizations Bring Hope for Indigenous Infants in the U.S.
American Indian and Alaska Native infants experience the highest rates of RSV-related hospitalization in the U.S., but a breakthrough immunization is helping to close the gap
www.scientificamerican.com
September 23, 2025 at 6:01 PM
American Indian and Alaska Native infants experience the highest rates of RSV-related hospitalization in the U.S., but a breakthrough immunization is helping to close the gap
🌍 97% of RSV-related infant deaths occur in low- & middle-income countries, where access to care is limited.
🔗 bit.ly/4klHdMH
🔗 bit.ly/4klHdMH
June 4, 2025 at 8:11 AM
🌍 97% of RSV-related infant deaths occur in low- & middle-income countries, where access to care is limited.
🔗 bit.ly/4klHdMH
🔗 bit.ly/4klHdMH
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/2023-24-rsv-vaccines-were-79-effective-against-virus-related-blood
⤷ canadahealthwatch.ca/featured 🍁
⤷ canadahealthwatch.ca/featured 🍁
February 19, 2026 at 3:31 PM
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/2023-24-rsv-vaccines-were-79-effective-against-virus-related-blood
⤷ canadahealthwatch.ca/featured 🍁
⤷ canadahealthwatch.ca/featured 🍁
‘Significant decline’ in RSV-related illness in babies after high uptake of jab
‘Significant decline’ in RSV-related illness in babies after high uptake of jab
Department of Health introduced new vaccination programme for babies last year
www.irishtimes.com
August 20, 2025 at 11:06 PM
‘Significant decline’ in RSV-related illness in babies after high uptake of jab
We're back, baby! #altMMWR returns after 7 weeks
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Nirsevimab Effectiveness Against Intensive Care Unit ...
This report describes a multicenter case-control investigation that found nirsevimab was 80% effective at preventing RSV-associated ICU admissions among infants.
www.cdc.gov
November 20, 2025 at 11:44 PM
We're back, baby! #altMMWR returns after 7 weeks
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
“The researchers found that nirsevimab reduced risk for RSV-LRTI-related hospitalization in the 2023 and 2024 birth cohorts relative to nonreceipt. Nirsevimab had an effectiveness of 66% to 72%.” www.infectiousdiseaseadvisor.com/news/nirsevi...
Nirsevimab Immunization Reduces RSV-LRTI Hospitalization
Nirsevimab immunization effectively decreases the risk for RSV-related LRTI hospitalizations in an infant's first year.
www.infectiousdiseaseadvisor.com
October 1, 2026 at 1:28 PM
“The researchers found that nirsevimab reduced risk for RSV-LRTI-related hospitalization in the 2023 and 2024 birth cohorts relative to nonreceipt. Nirsevimab had an effectiveness of 66% to 72%.” www.infectiousdiseaseadvisor.com/news/nirsevi...
From @jamapediatrics.com 💉🦠
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
Nirsevimab Immunization Reduces RSV-LRTI Hospitalization
Nirsevimab immunization effectively decreases the risk for RSV-related LRTI hospitalizations in an infant's first year.
www.infectiousdiseaseadvisor.com
September 30, 2026 at 5:41 PM
From @jamapediatrics.com 💉🦠
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates
www.cidrap.umn.edu/respiratory-...
www.cidrap.umn.edu/respiratory-...
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates
www.cidrap.umn.edu
February 19, 2026 at 4:30 AM
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates
www.cidrap.umn.edu/respiratory-...
www.cidrap.umn.edu/respiratory-...
RSV
As of March 3, 2026:
🔹13 states have RSV infections growing or likely growing
🔹19 states has infections declining or likely declining
🔹16 states shows no change
Source: cdc.gov/cfa-modeling...
As of March 3, 2026:
🔹13 states have RSV infections growing or likely growing
🔹19 states has infections declining or likely declining
🔹16 states shows no change
Source: cdc.gov/cfa-modeling...
March 9, 2026 at 10:04 PM
RSV
As of March 3, 2026:
🔹13 states have RSV infections growing or likely growing
🔹19 states has infections declining or likely declining
🔹16 states shows no change
Source: cdc.gov/cfa-modeling...
As of March 3, 2026:
🔹13 states have RSV infections growing or likely growing
🔹19 states has infections declining or likely declining
🔹16 states shows no change
Source: cdc.gov/cfa-modeling...
👶Spain’s paediatric wards “fell silent” after offering RSV monoclonal antibodies to every infant. Hospitalisations dropped sharply—and thousands of parents stayed at work.
Prevention isn’t just saving lives; it’s protecting families and economies.
INSIDE VIEW: @chrisnial.com
📖⬇️ & 🙏
Prevention isn’t just saving lives; it’s protecting families and economies.
INSIDE VIEW: @chrisnial.com
📖⬇️ & 🙏
Immunising For Prosperity: Why Europe Must Treat RSV And Pneumococcal Immunisation As An Economic Imperative - Health Policy Watch
After the country introduced monoclonal antibodies against Respiratory Syncytial Virus (RSV) for every infant, RSV-related hospitalisations dropped by 83%.
healthpolicy-watch.news
December 17, 2025 at 11:20 AM
👶Spain’s paediatric wards “fell silent” after offering RSV monoclonal antibodies to every infant. Hospitalisations dropped sharply—and thousands of parents stayed at work.
Prevention isn’t just saving lives; it’s protecting families and economies.
INSIDE VIEW: @chrisnial.com
📖⬇️ & 🙏
Prevention isn’t just saving lives; it’s protecting families and economies.
INSIDE VIEW: @chrisnial.com
📖⬇️ & 🙏
“… the medicine was 89% effective in preventing RSV-related hospitalization during the first season after the Yukon-Kuskokwim Health Corp., the region’s tribal provider, began administering it to babies last year…” #Vaccines #Alaska
New RSV drug delivers promising results in Alaska’s Yukon-Kuskokwim Delta • Alaska Beacon
In the rural Alaska region with the worst infant RSV problem, a preventative antibody appears to be moderating the disease's severity.
alaskabeacon.com
December 3, 2024 at 6:13 AM
Study found increase in RSV-associated hospitalizations in premature babies in N.S.
Some call for RSV vaccine to be available for all infants in the province
www.cbc.ca/news/canada/...
Some call for RSV vaccine to be available for all infants in the province
www.cbc.ca/news/canada/...
Study found increase in RSV-associated hospitalizations in premature babies in N.S. | CBC News
A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led to a tenfold increase in the number of infants in that group that were hos...
www.cbc.ca
January 29, 2025 at 12:35 PM
Study found increase in RSV-associated hospitalizations in premature babies in N.S.
Some call for RSV vaccine to be available for all infants in the province
www.cbc.ca/news/canada/...
Some call for RSV vaccine to be available for all infants in the province
www.cbc.ca/news/canada/...
In 2023-24, #RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates
Estimates didn’t differ substantially between immune-compromised and not–immune-compromised adults.
www.cidrap.umn.edu/r...
Estimates didn’t differ substantially between immune-compromised and not–immune-compromised adults.
www.cidrap.umn.edu/r...
February 18, 2026 at 9:50 PM
In 2023-24, #RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates
Estimates didn’t differ substantially between immune-compromised and not–immune-compromised adults.
www.cidrap.umn.edu/r...
Estimates didn’t differ substantially between immune-compromised and not–immune-compromised adults.
www.cidrap.umn.edu/r...
RSV
As of March 10, 2026:
🔹9 states have RSV infections growing or likely growing
🔹25 states has infections declining or likely declining
🔹14 states shows no change
Source: cdc.gov/cfa-modeling...
As of March 10, 2026:
🔹9 states have RSV infections growing or likely growing
🔹25 states has infections declining or likely declining
🔹14 states shows no change
Source: cdc.gov/cfa-modeling...
March 17, 2026 at 9:55 PM
RSV
As of March 10, 2026:
🔹9 states have RSV infections growing or likely growing
🔹25 states has infections declining or likely declining
🔹14 states shows no change
Source: cdc.gov/cfa-modeling...
As of March 10, 2026:
🔹9 states have RSV infections growing or likely growing
🔹25 states has infections declining or likely declining
🔹14 states shows no change
Source: cdc.gov/cfa-modeling...
Nirsevimab Reduces RSV-related Hospitalizations 80% in High-Risk Infants jamanetwork.com/journals/jam...
Nirsevimab in High-Risk Infants in an RSV Prevention Strategy
This case-control study evaluates the association of nirsevimab with the prevention of respiratory syncytial virus (RSV) infection among at-risk infants after implementation of a universal immunization strategy in Chile.
jamanetwork.com
April 11, 2026 at 3:17 AM
Nirsevimab Reduces RSV-related Hospitalizations 80% in High-Risk Infants jamanetwork.com/journals/jam...